prazosin has been researched along with Neurodegenerative Diseases in 3 studies
Prazosin: A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION.
prazosin : A member of the class of piperazines that is piperazine substituted by a furan-2-ylcarbonyl group and a 4-amino-6,7-dimethoxyquinazolin-2-yl group at positions 1 and 4 respectively.
Neurodegenerative Diseases: Hereditary and sporadic conditions which are characterized by progressive nervous system dysfunction. These disorders are often associated with atrophy of the affected central or peripheral nervous system structures.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Sardoiwala, MN | 1 |
| Mohanbhai, SJ | 1 |
| Karmakar, S | 1 |
| Choudhury, SR | 1 |
| Papay, R | 1 |
| Zuscik, MJ | 1 |
| Ross, SA | 1 |
| Yun, J | 1 |
| McCune, DF | 1 |
| Gonzalez-Cabrera, P | 1 |
| Gaivin, R | 1 |
| Drazba, J | 1 |
| Perez, DM | 1 |
| Seppi, K | 1 |
| Puschban, Z | 1 |
| Stefanova, N | 1 |
| Scherfler, C | 1 |
| Mueller, J | 1 |
| Poewe, W | 1 |
| Wenning, GK | 1 |
3 other studies available for prazosin and Neurodegenerative Diseases
| Article | Year |
|---|---|
Hytrin loaded polydopamine-serotonin nanohybrid induces IDH2 mediated neuroprotective effect to alleviate Parkinson's disease.
Topics: alpha-Synuclein; Dopamine; Humans; Indoles; Neurodegenerative Diseases; Neuroprotective Agents; Park | 2022 |
Mice expressing the alpha(1B)-adrenergic receptor induces a synucleinopathy with excessive tyrosine nitration but decreased phosphorylation.
Topics: Adrenergic alpha-Antagonists; alpha-Synuclein; Animals; Body Weight; Brain; Cerebellum; Disease Mode | 2002 |
Overstimulation of the alpha1B-adrenergic receptor causes a "seizure plus" syndrome.
Topics: Adrenergic alpha-Antagonists; Animals; Antiparkinson Agents; Brain; Cerebral Cortex; Disease Models, | 2001 |